Tumor-Targeted Salmonella
暂无分享,去创建一个
[1] P. Trail,et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. , 1993, Science.
[2] P. Friedman,et al. BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells. , 1993, Cancer research.
[3] K. Joiner. Complement evasion by bacteria and parasites. , 1988, Annual review of microbiology.
[4] L. Norton,et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.
[5] A. Giaccia,et al. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. , 1996, Gene therapy.
[6] R. C. Parker,et al. Effect of Histolyticus Infection and Toxin on Transplantable Mouse Tumors.∗ , 1947, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[7] F. Collins,et al. THE ROUTE OF ENTERIC INFECTION IN NORMAL MICE , 1974, The Journal of experimental medicine.
[8] C. Siegall. Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Le(y) antigen. , 1995, Seminars in cancer biology.
[9] P. Kourilsky,et al. Expression of herpes simplex virus type I thymidine kinase gene in Escherichia coli. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[10] P. V. Zijl,et al. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment , 1997, Gene Therapy.
[11] R K Jain,et al. Barriers to drug delivery in solid tumors. , 1994, Scientific American.
[12] A. Fattaey,et al. An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.
[13] J. Moese,et al. ONCOLYSIS BY CLOSTRIDIA. I. ACTIVITY OF CLOSTRIDIUM BUTYRICUM (M-55) AND OTHER NONPATHOGENIC CLOSTRIDIA AGAINST THE EHRLICH CARCINOMA. , 1964, Cancer research.
[14] R K Jain,et al. Tumor angiogenesis and interstitial hypertension. , 1996, Cancer research.
[15] T. Burrows,et al. The effects of biochemical mutation on the virulence of Bacterium typhosum: the virulence of mutants. , 1950, British journal of experimental pathology.
[16] T. Miyamoto,et al. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. , 1998, The Journal of urology.
[17] M. Saier,et al. Salmonella virulence: new clues to intramacrophage survival. , 1990, Trends in biochemical sciences.
[18] T. Burrows,et al. The effects of biochemical mutation on the virulence of Bacterium typhosum; the loss of virulence of certain mutants. , 1951, British journal of experimental pathology.
[19] D. Gericke,et al. ONCOLYSIS BY CLOSTRIDIA. V. TRANSPLANTED TUMORS OF THE HAMSTER. , 1964, Cancer research.
[20] B. Stocker,et al. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines , 1981, Nature.
[21] J. Pawelek,et al. Tumor-targeted Salmonella as a novel anticancer vector. , 1997, Cancer research.
[22] I. Charles,et al. A lethal role for lipid A in Salmonella infections , 1998, Molecular microbiology.
[23] E. Neter,et al. Clostridial oncolysis in man , 1967 .